Dr. Thomas Dayspring, a world-renowned lipidologist, explores the science of cholesterol and its carriers—lipoproteins—and their role in heart disease. 

He highlights the importance of measuring ApoB for a more accurate assessment of cardiovascular risk and discusses emerging therapies that target ApoB and Lp(a), providing new options for heart disease prevention and treatment.

Bio

Thomas Dayspring, MD is a Fellow of both the American College of Physicians and the National Lipid Association and is certified in internal medicine, and clinical lipidology. After practicing in New Jersey for 37 years, in 2012 he moved to Virginia and served as an educational director for a nonprofit cardiovascular foundation and until mid-2019 as a Chief Academic Advisor for two major CV laboratories. Since then, he has served as a virtual cardiovascular / lipidology educator. 
 

Career-wise he has given over 4000 domestic and several international lectures, including over 600 CME programs on atherothrombosis, lipids/lipoproteins (and their treatment), vascular biology, biomarker testing, and women’s cardiovascular issues. He has authored several manuscripts and lipid textbook chapters and appeared on multiple podcasts, including The Drive with Dr. Peter Attia. 
 

For several years he was an Associate Editor of the Journal of Clinical Lipidology. He was the recipient of the 2011 National Lipid Association’s President's Award for services to clinical lipidology and the 2023 Foundation of NLA Clinician/Educator Award. He has over 38K followers on his educational Twitter (X) feed (@Drlipid). He has Gold Heart Member status as a professional member of the American Heart Association and serves as a Social Media Ambassador for the European Atherosclerosis Society and for the National Lipid Association.
 

4 Key Takeaways

1. Apolipoprotein B (ApoB) is the best predictor of cardiovascular disease: Dr. Dayspring explains why the real focus should be on the number of atherogenic particles measured via ApoB, rather than the cholesterol content of those particles, which appears on the standard lipid panel.
2. Lp(a): He defines Lp(a) and discusses the dangers associated with its presence in the circulation.
3. Future Therapies: Dr. Dayspring highlights emerging therapies that target Lp(a) and other lipoproteins, which could shift how we approach cholesterol management in the future.
4. Understanding Lipid Panels: Many doctors and patients don’t fully understand lipid panel results. Dr. Dayspring explains what the numbers really mean and how to use them effectively to manage cardiovascular health.

Let’s connect…

• Work with Me: Premier Cardiovascular Health and Performance
• Facebook: @PremierCardioHealth
• Instagram: @PremierCardioHealth

Disclaimer: The information provided in this podcast is for educational and informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider before making any decisions about your health or medical treatment.